Novel and Founder Pathogenic Variants in X-Linked Alport Syndrome Families in Greece
Despina Hadjipanagi,Gregory Papagregoriou,Constantina Koutsofti,Christiana Polydorou,Polichronis Alivanis,Aimilios Andrikos,Stalo Christodoulidou,Manthos Dardamanis,Athanasios A Diamantopoulos,Anastasios Fountoglou,Eleni Frangou,Eleni Georgaki,Ioannis Giannikouris,Velissarios Gkinis,Pavlos C Goudas,Rigas G Kalaitzidis,Nikolaos Kaperonis,Georgios Koutroumpas,George Makrydimas,Grigorios Myserlis,Andromachi Mitsioni,Christos Paliouras,Fotios Papachristou,Dorothea Papadopoulou,Nikolaos Papagalanis,Aikaterini Papagianni,Garyfalia Perysinaki,Ekaterini Siomou,Konstantinos Sombolos,Ioannis Tzanakis,Georgios V Vergoulas,Nicoletta Printza,Constantinos Deltas
DOI: https://doi.org/10.3390/genes13122203
2022-11-24
Abstract:Alport syndrome (AS) is the most frequent monogenic inherited glomerulopathy and is also genetically and clinically heterogeneous. It is caused by semi-dominant pathogenic variants in the X-linked COL4A5 (NM_000495.5) gene or recessive variants in the COL4A3/COL4A4 (NM_000091.4/NM_000092.4) genes. The disease manifests in early childhood with persistent microhematuria and can progress to proteinuria and kidney failure in adolescence or early adulthood if left untreated. On biopsy, pathognomonic features include alternate thinning, thickening and lamellation of the glomerular basement membrane (GBM), in the presence of podocyte foot process effacement. Although previous studies indicate a prevalence of AS of about 1/50,000, a recent publication reported a predicted rate of pathogenic COL4A5 variants of 1/2320. We herewith present 98 patients (40 M/58 F) from 26 Greek families. We are selectively presenting the families segregating the X-linked form of AS with pathogenic variants in the COL4A5 gene. We found 21 different pathogenic variants, 12 novel: eight glycine and one proline substitutions in the collagenous domain, one cysteine substitution in the NC1 domain, two premature termination of translation codons, three splicing variants, one 5-bp insertion/frameshift variant, one indel-frameshift variant and four gross deletions. Notably, patients in six families we describe here and three families we reported previously, carried the COL4A5-p.G624D substitution, a founder defect encountered all over Europe which is hypomorphic with mostly milder symptomatology. Importantly, on several occasions, the correct genetic diagnosis reclassified patients as patients with AS, leading to termination of previous immunosuppressive/cyclosporine A therapy and a switch to angiotensin converting enzyme inhibitors (ACEi). With the understanding that all 98 patients span a wide range of ages from infancy to late adulthood, 15 patients (11 M/4 F) reached kidney failure and 11 (10 M/1 F) received a transplant. The prospects of avoiding lengthy diagnostic investigations and erroneous medications, and the advantage of delaying kidney failure with very early administration of renin-angiotensin-aldosterone system (RAAS) blockade, highlights the importance of timely documentation of AS by genetic diagnosis.